RYTM
Price:
$59.94
Market Cap:
$3.68B
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesit...[Read more]
Industry
Biotechnology
IPO Date
2017-10-09
Stock Exchange
NASDAQ
Ticker
RYTM
According to Rhythm Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -369.26%. This represents a change of 100.39% compared to the average of -184.27% of the last 4 quarters.
The mean historical ROE of Rhythm Pharmaceuticals, Inc. over the last ten years is 104.28%. The current -369.26% ROE has changed -454.12% with respect to the historical average. Over the past ten years (40 quarters), RYTM's ROE was at its highest in in the March 2015 quarter at 224.57%. The ROE was at its lowest in in the September 2024 quarter at -400.98%.
Average
104.28%
Median
-41.25%
Minimum
-354.56%
Maximum
1.81%
Discovering the peaks and valleys of Rhythm Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.76%
Maximum Annual ROE = 1.81%
Minimum Annual Increase = -101.91%
Minimum Annual ROE = -354.56%
Year | ROE | Change |
---|---|---|
2023 | -108.79% | 57.03% |
2022 | -69.28% | 189.47% |
2021 | -23.93% | -69.51% |
2020 | -78.50% | 63.87% |
2019 | -47.91% | 59.28% |
2018 | -30.08% | 29.18% |
2017 | -23.28% | -93.43% |
2016 | -354.56% | 924.67% |
2015 | -34.60% | -101.91% |
2014 | 1.81% | 4.76% |
The current ROE of Rhythm Pharmaceuticals, Inc. (RYTM) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-67.33%
5-year avg
-65.68%
10-year avg
104.28%
Rhythm Pharmaceuticals, Inc.’s ROE is greater than Revolution Medicines, Inc. (-33.67%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Avidity Biosciences, Inc. (-27.66%), less than Protagonist Therapeutics, Inc. (34.68%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than uniQure N.V. (-188.82%), greater than Rocket Pharmaceuticals, Inc. (-62.62%), greater than Solid Biosciences Inc. (-58.75%), greater than MeiraGTx Holdings plc (-80.95%), greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than Arcellx, Inc. (-8.28%), greater than Cullinan Oncology, Inc. (-26.54%), less than Kiniksa Pharmaceuticals, Ltd. (-2.08%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Syndax Pharmaceuticals, Inc. (-64.34%), greater than Viridian Therapeutics, Inc. (-45.47%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Relay Therapeutics, Inc. (-45.75%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Arvinas, Inc. (-50.26%),
Company | ROE | Market cap |
---|---|---|
-33.67% | $9.55B | |
-32.52% | $2.28B | |
-27.66% | $5.16B | |
34.68% | $2.77B | |
-54.45% | $605.41M | |
-188.82% | $281.74M | |
-62.62% | $1.29B | |
-58.75% | $216.15M | |
-80.95% | $463.45M | |
-28.63% | $6.75B | |
-54.94% | $130.81M | |
-8.28% | $4.89B | |
-26.54% | $730.17M | |
-2.08% | $1.54B | |
-48.91% | $789.88M | |
-64.34% | $1.37B | |
-45.47% | $1.60B | |
-88.42% | $180.51M | |
-45.75% | $795.07M | |
-68.08% | $143.73M | |
-50.26% | $1.78B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rhythm Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rhythm Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Rhythm Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Rhythm Pharmaceuticals, Inc. (RYTM)?
What is the highest ROE for Rhythm Pharmaceuticals, Inc. (RYTM)?
What is the 3-year average ROE for Rhythm Pharmaceuticals, Inc. (RYTM)?
What is the 5-year average ROE for Rhythm Pharmaceuticals, Inc. (RYTM)?
How does the current ROE for Rhythm Pharmaceuticals, Inc. (RYTM) compare to its historical average?